Ebola vaccine development
Ebola vaccine development started in the year 2000s because of the threat of bioterrorism attacks with the Ebola virus. Scientists used several different viral vector platforms, the leading ones being human and chimpanzee adenovirus, rabies virus, alphavirus replicons, paramyxoviruses and different strategies with recombinant vesicular stomatitis virus (rVSV) and modified vaccinia virus Ankara (MVA). 1 The main viral antigen included in the vaccine candidate is the filovirus transmembrane glycoprotein (GP) since it is recognized as the main target for neutralizing antibodies; it is used in various conformations (full length, ormucin domain deleted, transmembrane anchor deleted). Most of the pre-clinical studies showed an efficacy of 100% in protecting non-human primates (NHP) when challenged 28 days after one injection of the vaccine candidate.
During and after the 2013-2016 Ebola epidemic, several of these vaccine candidates were assessed in about 50 phase 1-3 clinical trials. These trials included mainly rVSV-EBOV, 2 rVSV-EBOV combined with Ad5-EBOV, 3 ChAd3-EBOV with or without MVA-EBOV 4,5 and Ad26-EBOV combined with MVA-EBOV. 6 Most of these trials assessed safety and immunogenicity (Table 1 ). In general, all of these vaccines showed no serious adverse effects and induced immune responses that were close to those that conferred full protection in NHP. Several rVSV-EBOV phase 1 trials, however, reported arthritis and rash. In one particular trial conducted in Geneva, of the 51 participants, 13 (25%) developed arthritis in the second week after vaccination. Moreover, a mild maculopapular rash developed in seven participants who had arthritis. However, since the concentration of EBOV GP-specific and neutralizing antibodies was significantly lower in those vaccinated with a low dose than with a high dose and because individuals who received the low-dose vaccination still developed arthritis, it was decided to proceed with the high dose in the phase 3 clinical trials in Africa 7 . Of note is that these adverse events following immunization (AEFI) were not observed, or were less observed, in further trials conducted in epidemic areas. 2 The first and only efficacy trial was an open-label, clusterrandomized ring vaccination with rVSV-EBOV phase 3 in Guinea. In this trial, contacts and contacts of contacts of individuals with EVD were grouped into clusters and these clusters were randomized to receive a single dose of the VSV-EBOV vaccine immediately or with a 21-day delay. AEFI were mild in general, and very little arthritis was observed. More importantly, no cases of EVD occurred 10 or more days after randomization among, the 4539 randomly assigned contacts vaccinated in immediate clusters, while 16 cases were diagnosed in the 4557 receiving the vaccine with the 21-day delay. 8 Since then, this vaccine has been used successfully in health-care professionals and in contacts of index cases using the ring vaccination strategy during the two recent outbreaks in DRC.
Despite these promising results, rVSV-EBOV is still awaiting for licensure, two years after the first trial, while Russia licensed a combination vaccine approach using an rVSV-EBOV prime and Ad5-EBOV boost, based on few pre-clinical data and one phase 1/2 trial only. 3 The same process was followed in China that licensed an Ad5-based EBOV vaccine. 9 Both vaccine components are similar to those included in the two rVSV-EBOV and Ad5-EBOV candidates developed and evaluated in North America, Europe and Africa. Awaiting approval by FDA, 300,000 doses of rVSV-EBOV have been committed as stockpile to be used during outbreak under the appropriate regulatory mechanism (IND or EUA).
Use in humanitarian workers
Although there is little doubt that Ebola vaccines should be used to complement evidence-based strategies to prevent the acquisition and spread of EBV, clear guidance for their use in humanitarian health workers sent temporarily to affected zones is lacking. Doctors without borders (MSF), WHO employees, etc. are offered the vaccine (compassionate use), should they want it. They are not forced and can choose to be injected or not, without any further consequence on the care they are entitled to.
However, there are some questions that are yet to be answered, namely, what is the true balance of risk/benefit considering the safety profile of the vaccine (potential of arthritis), the probable delay in protection after vaccination on-site (10 days?), the duration of protection (one year?) and the degree of crossprotection against different Ebola virus strains and species.
The question of risk/benefit should be raised since the safety profile of the rVSV-EBOV vaccine in Caucasian populations, such as that in Switzerland, for example, is not optimal. One subject out of 5 developed arthritis (not arthralgia which is a common AEFI) in Geneva, 7 lasting for more than a month in some participants. This should be balanced with the degree of protection conferred by the vaccine in this particular population. Indeed, since the vaccine is generally not available in Europe or the USA (for the time being), the humanitarian workers are being vaccinated upon arrival in the epidemic zone. This means that they are still at risk for the first 10 days following vaccination. Usually, they stay only for up to six weeks because of work stress. The benefit is therefore not as much for humanitarian workers as it is for the local health professionals who will work on-site for the whole duration of the epidemic, which can last for months. The little experience accumulated so far shows that a significant proportion of the humanitarian health workers choose not to be vaccinated, the most common reason to decline being the fear of suffering from AEFI, which would prevent them from working, rendering them useless on-site. Also, there is some worry that AEFI such as malaise, or even fever, may mimic EBV disease.
How do the pre-clinical studies help in answering the above questions?
After demonstrating the pre-exposure efficacy of the rVSV-EBOV vaccine in humans, further animal studies were conducted to evaluate the potential of rVSV-EBOV as an emergency vaccine, either shortly before or after exposure to EBOV, which would be the case for the humanitarian worker. These studies showed that 50% of NHP with rVSV-EBOV at 1 and/or 24 h after lethal EBOV challenge survived, indicating some degree of post-exposure protective efficacy of rVSV-EBOV. It is therefore feasible to use rVSV in epidemic situation but protection would not be optimal. Cross-protection of the rVSV-EBOV vaccine within the Zaire Ebola virus species was demonstrated in several animal studies. NHP vaccinated with rVSV-EBOV and then challenged with heterologous strains were well protected. 11 Thus, the currently available rVSV-EBOV vaccine can be used with reasonable confidence in future EBOV outbreaks. The potential for crossprotection between different Ebola virus species (Bundibugyo, Taï Forest, Reston or Sudan ebola virus) was investigated in several animal studies. Results were variable depending on the animals studied, the type of virus that was expressed by viral vectors, and the vaccine regimen (e.g. one shot or prime boost). The conclusion is that there is little cross-protection between species. The latter is more likely to be obtained using other approaches such as mixing several monovalent viral vectors expressing the glycoproteins of different Ebola virus species or expression of additional viral proteins from a multivalent viral vector.
In terms of duration of protection, longitudinal studies have shown that the humoral response induced by a single injection of rVSV-EBOV vaccine persisted for at least 1-2 years across different populations in different continents and with different doses. 10, 11 The kinetics of the glycoprotein-specific IgG antibodies were typical of other live-attenuated vaccines, which leave hope for long-term protection, but this needs to be confirmed in the field.
Conclusion
Humanitarian health workers are likely to benefit from vaccination with rVSV-EBOV vaccine when deployed in epidemic zones, even at the start of an outbreak when the strain of the virus has not yet been identified. There is certainly some time lag to full protection, probably around 7-10 days, as demonstrated in the first efficacy trial. There are still some grey areas, including the true incidence of AEFI such as arthritis in Caucasian populations; the safety of the vaccine in immunocompromised subjects, although preliminary data are reassuring; the true level of cross-protection between Ebola virus strains and species in humans; as well as the duration of full protection. Considering the rather low level of rVSV vaccine uptake in humanitarian workers, this highlights a requirement to consider how best to address concerns and provide accurate information to this population. Licensure as well as availability of the vaccine prior to departure rather than on-site is highly desirable to address the above issues. The development and rigorous field testing of other vaccines than rVSV-EBOV with different technology platforms and different vaccine strategies (prime boost for long-term protection), and including new species, or even other viruses (Marburg, Lassa) should definitely be promoted to fight further outbreaks.
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